Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumor, Adult 1

Interventions

pembrolizumab 3Ipilimumab 2Blood Specimen Collection 2spartalizumab 1necitumumab 1mirdametinib 1leronlimab 1apatinib 1Watchful Waiting 1Tomography, X-Ray Computed 1Therapeutics 1Surveys and Questionnaires 1Rosuvastatin Calcium 1Radiotherapy 1Radiation 1Positron-Emission Tomography 1PankoMab-GEX 1Panitumumab 1Nivolumab 1Metformin 1Magnetic Resonance Imaging 1MEK inhibitor I 1Jupiter 1JPT1 protein, human 1Interleukin-2 1Immune Checkpoint Inhibitors 1GAT 1Fluorodeoxyglucose F18 1FCN-437c 1EBI-005 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Solid Tumor, Adult × Jupiter × Clear all
NCT04020185 2024-12-11

Safety and Efficacy Study of IMSA101 in Refractory Malignancies

ImmuneSensor Therapeutics Inc.

Phase 1/2 Completed
40 enrolled 16 charts
Other solid neoplasm

Solid Tumor, Adult

Data powered by HemOnc (CC BY 4.0) Colophon âš¡